Neurogene Inc. Appoints New Directors, Adjusts Executive Compensation
Ticker: NGNE · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1404644
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: NGNE
TL;DR
Neurogene adds new board members & adjusts exec pay. Big changes coming?
AI Summary
Neurogene Inc. announced on April 1, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Steven M. Altschuler and Dr. Steven A. Williams have been appointed to the Board of Directors. The company also reported on compensatory arrangements for its named executive officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy and governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes, along with compensation adjustments, can introduce uncertainty and signal strategic shifts that may carry inherent risks.
Key Players & Entities
- Neurogene Inc. (company) — Registrant
- Dr. Steven M. Altschuler (person) — Appointed to Board of Directors
- Dr. Steven A. Williams (person) — Appointed to Board of Directors
- April 1, 2024 (date) — Date of earliest event reported
FAQ
Who were the individuals appointed to Neurogene Inc.'s Board of Directors?
Dr. Steven M. Altschuler and Dr. Steven A. Williams were appointed to the Board of Directors.
What is the effective date of the reported changes?
The date of the earliest event reported is April 1, 2024.
What specific items are covered in this 8-K filing?
This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What was Neurogene Inc.'s former name?
Neurogene Inc. was formerly known as Neoleukin Therapeutics, Inc., Aquinoix Pharmaceuticals, Inc., and Aquinoix Pharmaceuticals (USA) Inc.
Where is Neurogene Inc. headquartered?
Neurogene Inc. is headquartered at 535 W 24th Street, 5th Floor, New York, NY 10011.
Filing Stats: 1,014 words · 4 min read · ~3 pages · Grade level 11.6 · Accepted 2024-04-02 15:43:33
Key Financial Figures
- $0.000001 — ange on which registered Common Stock, $0.000001 par value NGNE The Nasdaq Global Market
- $595,000 — ment, her initial annual base salary is $595,000, subject to increases from time to time
- $515,000 — er initial annual base salary is set at $515,000, (b) her annual performance bonus is ta
Filing Documents
- ngne-20240401.htm (8-K) — 29KB
- 0001404644-24-000026.txt ( ) — 154KB
- ngne-20240401.xsd (EX-101.SCH) — 2KB
- ngne-20240401_lab.xml (EX-101.LAB) — 22KB
- ngne-20240401_pre.xml (EX-101.PRE) — 13KB
- ngne-20240401_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: April 2, 2024 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer